Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|KW-2450||KW2450|KW 2450||Aurka Inhibitors 24 Aurkb Inhibitors 20 IGF-1R Inhibitor 17||KW-2450 is a multitargeted kinase inhibitor with activity against Aurora A and B, and IGF-1R, which potentially results in decreased tumor cell growth (PMID: 26443806, PMID: 30083253).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||KW-2450||Preclinical||Actionable||In a preclinical study, KW-2450 inhibited the growth of triple-negative breast cancer cells in culture and in xenograft models (PMID: 26443806).||26443806|
|Unknown unknown||breast cancer||not applicable||KW-2450||Preclinical||Actionable||In a preclinical study, KW-2450 inhibited growth of several breast cancer cell lines in culture, including ESR1 positive, ERBB2 (HER2) positive/ESR1 positive, ERBB2 (HER2) positive, and triple-negative subtypes (PMID: 26443806).||26443806|
|Unknown unknown||Advanced Solid Tumor||not applicable||KW-2450||Phase I||Actionable||In a Phase I trial, 40% (4/10) of patients with advanced solid tumors demonstrated stable disease when treated with KW-2450 (PMID: 26850678).||26850678|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|